Elanco Innovation Builds Momentum, Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) Reaches Blockbuster Status
1. Credelio Quattro reaches $100 million in net sales in under eight months. 2. Credelio Quattro offers broadest parasite protection, capturing 14% U.S. market share in June. 3. Zenrelia launched in EU and UK, offering a daily treatment for skin allergies. 4. Elanco plans global market expansion for Credelio Quattro starting in 2026. 5. Human Lyme disease cases rise, increasing demand for effective pet parasite treatments.